

Chrisandra L Shufelt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/902964/publications.pdf>

Version: 2024-02-01

143
papers

3,934
citations

159358

30
h-index

149479

56
g-index

187
all docs

187
docs citations

187
times ranked

4641
citing authors

#	ARTICLE	IF	CITATIONS
1	Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease. <i>American Heart Journal Plus</i> , 2022, 13, 100115.	0.3	1
2	Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women. <i>Circulation Research</i> , 2022, 130, 652-672.	2.0	110
3	Sex-based differences in remote monitoring of biometric, psychometric and biomarker indices in stable ischemic heart disease. <i>Biology of Sex Differences</i> , 2022, 13, 15.	1.8	1
4	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials. <i>Contemporary Clinical Trials</i> , 2022, 117, 106762.	0.8	6
5	Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Internal Medicine</i> , 2022, 182, 587.	2.6	4
6	Subclinical cardiovascular disease and polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2022, 117, 912-923.	0.5	18
7	Internal Medicine Resident Education Improves Cardiac Rehabilitation Knowledge, Attitude, and Referral Rates: A Pilot Study. <i>American Journal of Preventive Cardiology</i> , 2022, , 100349.	1.3	0
8	The Menopause Management Vacuum. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 191-195.	1.0	3
9	Phytoestrogen blood levels and adverse outcomes in women with suspected ischemic heart disease. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 829-835.	1.3	4
10	Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1245-1254.	1.8	34
11	Coronary Microvascular Dysfunction. , 2021, , 141-158.		1
12	Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease. <i>Journal of Women's Health</i> , 2021, 30, 377-384.	1.5	4
13	Don't weight until menopause: identifying cardiovascular risk during the transition. <i>Menopause</i> , 2021, 28, 608-609.	0.8	1
14	Diastolic dysfunction in women with ischemia and no obstructive coronary artery disease: Mechanistic insight from magnetic resonance imaging. <i>International Journal of Cardiology</i> , 2021, 331, 1-7.	0.8	8
15	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. <i>Menopause</i> , 2021, 28, 610-618.	0.8	13
16	Current Perspective on Menopause Hormone Therapy and Cardiovascular Risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	2
17	Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease. <i>International Journal of Cardiology</i> , 2021, 333, 35-39.	0.8	10
18	Statin therapy in midlife women. <i>Menopause</i> , 2021, 28, 1067-1069.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women's Health Initiative Observational Study (WHI-OS). <i>Menopause</i> , 2021, 28, 1108-1116.	0.8	5
20	Risk factors for heart failure in women with ischemia and no obstructive coronary artery disease. <i>American Heart Journal Plus</i> , 2021, 8, 100035.	0.3	0
21	Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women's Ischemia Syndrome Evaluation's Coronary Vascular Dysfunction (WISE-CVD) study. <i>PLoS ONE</i> , 2021, 16, e0257184.	1.1	11
22	Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. <i>Clinical Cardiology</i> , 2021, 44, 1586-1593.	0.7	2
23	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. <i>Maturitas</i> , 2021, 151, 55-62.	1.0	28
24	Coronary microvascular dysfunction: Considerations for diagnosis and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 561-571.	0.6	15
25	Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project. , 2021, 5, .		0
26	Gender-Related Differences in Chest Pain Syndromes in the Frontiers in CV Medicine Special Issue: Sex & Gender in CV Medicine. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 744788.	1.1	14
27	Feasibility of Patient-Centric Remote Dried Blood Sampling: The Prediction, Risk, and Evaluation of Major Adverse Cardiac Events (PRE-MACE) Study. <i>Biodemography and Social Biology</i> , 2020, 65, 313-322.	0.4	7
28	A Machine Learning Approach to Classifying Self-Reported Health Status in a Cohort of Patients With Heart Disease Using Activity Tracker Data. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 878-884.	3.9	45
29	Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation's Coronary Vascular Dysfunction (WISE-CVD). <i>American Heart Journal</i> , 2020, 220, 224-236.	1.2	15
30	The Masquerading, Masculinizing Tumor: A Case Report and Review of the Literature. <i>Journal of Women's Health</i> , 2020, 30, 1047-1051.	1.5	3
31	Left ventricular mass and myocardial scarring in women with hypertensive disorders of pregnancy. <i>Open Heart</i> , 2020, 7, e001273.	0.9	6
32	After menopause, is an enlarging middle, an enlarging cardiovascular risk factor?. <i>Menopause</i> , 2020, 27, 974-975.	0.8	1
33	Hormonal Contraception in Women With Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1451.	3.8	17
34	Can We Improve Cardiovascular Disease for Women Using Data Under Our Noses?. <i>JAMA Cardiology</i> , 2020, 5, 1398.	3.0	5
35	Biometric and Psychometric Remote Monitoring and Cardiovascular Risk Biomarkers in Ischemic Heart Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e016023.	1.6	8
36	Ambulatory and silent myocardial ischemia in women with coronary microvascular dysfunction: Results from the Cardiac Autonomic Nervous System study (CANS). <i>International Journal of Cardiology</i> , 2020, 316, 1-6.	0.8	11

#	ARTICLE	IF	CITATIONS
37	Even "WISE-R" an Update on the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation. <i>Current Atherosclerosis Reports</i> , 2020, 22, 35.	2.0	6
38	Resting coronary velocity and myocardial performance in women with impaired coronary flow reserve: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. <i>International Journal of Cardiology</i> , 2020, 309, 19-22.	0.8	12
39	Aspirin for primary prevention of cardiovascular disease in women. <i>Menopause</i> , 2020, 27, 605-606.	0.8	2
40	Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1-Year Follow-Up: Results From WISE-CVD. <i>Journal of the American Heart Association</i> , 2020, 9, e016305.	1.6	4
41	Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease: A Report from the WISE (Women's Ischemia Syndrome Evaluation) Study. <i>Journal of the American Heart Association</i> , 2020, 9, e013168.	1.6	10
42	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome) Tj ETQq0 0 0 rgBT /Overlock 10.8f 50 537	1.6	0
43	N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. <i>PLoS ONE</i> , 2020, 15, e0243213.	1.1	3
44	Abstract 16281: Non-calcified Coronary Plaque Burden is Related to Epicardial Adipose Tissue and Peri-coronary Adipose Tissue Attenuation in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, .	1.6	0
45	RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES AND CARDIAC BIOMARKERS: THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY BASELINE RESULTS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1831.	1.2	1
46	HYPERCONTRACTILITY IN WOMEN WITH HIGH RESTING CORONARY VELOCITY AND LOW CORONARY FLOW RESERVE: RESULTS FROM THE WOMEN'S ISCHEMIA SYNDROME EVALUATION-CORONARY VASCULAR DYSFUNCTION (WISE-CVD) PROJECT. <i>Journal of the American College of Cardiology</i> , 2019, 73, 35.	1.2	0
47	Cardiovascular implications of gender-affirming hormone treatment in the transgender population. <i>Maturitas</i> , 2019, 129, 45-49.	1.0	35
48	A protocol integrating remote patient monitoring patient reported outcomes and cardiovascular biomarkers. <i>Npj Digital Medicine</i> , 2019, 2, 84.	5.7	12
49	Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. <i>Journal of the American Heart Association</i> , 2019, 8, e012406.	1.6	56
50	Cardiovascular and pregnancy outcomes in women with coronary microvascular dysfunction: a case series. <i>European Heart Journal - Case Reports</i> , 2019, 3, .	0.3	1
51	Progression of coronary microvascular dysfunction to heart failure with preserved ejection fraction: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 134.	0.4	3
52	SYMPTOMATIC MYOCARDIAL BRIDGING AND CORONARY VASOMOTOR DYSFUNCTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2846.	1.2	5
53	Vascular Function and Serum Lipids in Women with Spontaneous Preterm Delivery and Term Controls. <i>Journal of Women's Health</i> , 2019, 28, 1522-1528.	1.5	4
54	Hormone therapy and carotid intima-media thickness: the thick and thin of it. <i>Menopause</i> , 2019, 26, 5-6.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Vascular Aging Is Accelerated in Flight Attendants With Occupational Secondhand Smoke Exposure. <i>Journal of Occupational and Environmental Medicine</i> , 2019, 61, 197-202.	0.9	2
56	A clinical prescription for heart health in midlife women. <i>Maturitas</i> , 2019, 119, 46-53.	1.0	4
57	Early Detection of Atrial Fibrillation-Atrial Flutter Using Remote Patient Monitoring. <i>Journal of Medical Cases</i> , 2019, 10, 31-36.	0.4	1
58	Association of Spontaneous Preterm Delivery and Future Maternal Cardiovascular Disease. <i>Circulation</i> , 2018, 137, 865-871.	1.6	41
59	Myocardial Scar Is Prevalent and Associated With Subclinical Myocardial Dysfunction in Women With Suspected Ischemia But No Obstructive Coronary Artery Disease. <i>Circulation</i> , 2018, 137, 874-876.	1.6	23
60	Mental stress peripheral vascular reactivity is elevated in women with coronary vascular dysfunction: Results from the NHLBI-sponsored Cardiac Autonomic Nervous System (CANS) study. <i>International Journal of Cardiology</i> , 2018, 251, 8-13.	0.8	21
61	Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines. <i>European Heart Journal</i> , 2018, 39, 3451-3453.	1.0	12
62	Women's health. <i>Current Opinion in Cardiology</i> , 2018, 33, 506-513.	0.8	2
63	Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <i>Menopause</i> , 2018, 25, 985-991.	0.8	14
64	Evaluating utility and compliance in a patient-based eHealth study using continuous-time heart rate and activity trackers. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 1386-1391.	2.2	37
65	Sex-Specific Physiology and Cardiovascular Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1065, 433-454.	0.8	96
66	Maladaptive left ventricular remodeling in women: An analysis from the Women's Ischemia Syndrome Evaluation—Coronary Vascular Dysfunction study. <i>International Journal of Cardiology</i> , 2018, 268, 230-235.	0.8	3
67	Managing Menopause by Combining Evidence With Clinical Judgment. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 470-479.	0.6	4
68	False—positive stress testing: Does endothelial vascular dysfunction contribute to ST—segment depression in women? A pilot study. <i>Clinical Cardiology</i> , 2018, 41, 1044-1048.	0.7	5
69	Lesser Severity of Recurrent Takotsubo Cardiomyopathy While Taking Angiotensin II Receptor Blocker and Beta Blocker. <i>Journal of Medical Cases</i> , 2018, 9, 201-203.	0.4	0
70	Inter-scan Reproducibility of Cardiovascular Magnetic Resonance Imaging-Derived Myocardial Perfusion Reserve Index in Women with no Obstructive Coronary Artery Disease. <i>Current Trends in Clinical & Medical Imaging</i> , 2018, 2, .	0.2	3
71	Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). <i>Menopause</i> , 2017, 24, 126-132.	0.8	58
72	Cardiac autonomic function and vasomotor symptoms: too much break and not enough accelerator?. <i>Menopause</i> , 2017, 24, 719-721.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve. <i>Clinical Cardiology</i> , 2017, 40, 886-891.	0.7	7
74	Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine. <i>Clinical Cardiology</i> , 2017, 40, 300-306.	0.7	22
75	Role of Stress Cardiac Magnetic Resonance Imaging in Women With Suspected Ischemia But No Obstructive Coronary Artery Disease. <i>Journal of Radiology Nursing</i> , 2017, 36, 180-183.	0.2	6
76	Premature atherosclerosis in premenopausal women: Does cytokine balance play a role?. <i>Medical Hypotheses</i> , 2017, 109, 38-41.	0.8	2
77	Sex differences in coronary heart disease risk factors: rename it ischaemic heart disease!. <i>Heart</i> , 2017, 103, 1567-1568.	1.2	13
78	Reassurance for many healthy women considering HRT. <i>BMJ: British Medical Journal</i> , 2017, 359, j4652.	2.4	2
79	Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2017, 24, 1145-1153.	0.8	26
80	Hypothalamic Amenorrhea and the Long-Term Health Consequences. <i>Seminars in Reproductive Medicine</i> , 2017, 35, 256-262.	0.5	84
81	Cold Pressor Stress Cardiac Magnetic Resonance Myocardial Flow Reserve Is Not Useful for Detection of Coronary Endothelial Dysfunction in Women with Signs and Symptoms of Ischemia and No Obstructive CAD. <i>PLoS ONE</i> , 2017, 12, e0169818.	1.1	2
82	Acetylcholine versus cold pressor testing for evaluation of coronary endothelial function. <i>PLoS ONE</i> , 2017, 12, e0172538.	1.1	13
83	Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. <i>JMIR Research Protocols</i> , 2017, 6, e255.	0.5	11
84	Diastolic dysfunction measured by cardiac magnetic resonance imaging in women with signs and symptoms of ischemia but no obstructive coronary artery disease. <i>International Journal of Cardiology</i> , 2016, 220, 775-780.	0.8	14
85	Carotid artery distensibility and hormone therapy and menopause. <i>Menopause</i> , 2016, 23, 150-157.	0.8	7
86	A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. <i>European Heart Journal</i> , 2016, 37, 1504-1513.	1.0	152
87	Heart failure hospitalization in women with signs and symptoms of ischemia: A report from the women's ischemia syndrome evaluation study. <i>International Journal of Cardiology</i> , 2016, 223, 936-939.	0.8	28
88	Subclinical systolic and diastolic dysfunction in women with signs and symptoms of ischemia but no obstructive coronary disease: novel insights using myocardial feature tracking in the NHLBI WISE study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, O3.	1.6	0
89	The Potential for Postrandomization Confounding in Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2273.	3.8	39
90	Prior myocardial infarction is associated with coronary endothelial dysfunction in women with signs and symptoms of ischemia and no obstructive coronary artery disease. <i>International Journal of Cardiology</i> , 2016, 207, 137-139.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Preeclampsia and Vascular Function: A Window to Future Cardiovascular Disease Risk. <i>Journal of Women's Health</i> , 2016, 25, 284-291.	1.5	49
92	Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 78-86.	0.7	18
93	Do women with statin-related myalgias have low vitamin D levels?. <i>BMC Research Notes</i> , 2015, 8, 449.	0.6	6
94	Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	184
95	Hormone therapy in menopause: An update on cardiovascular disease considerations. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 540-549.	2.3	23
96	Calcium Supplements and Cardiovascular Disease. <i>American Journal of Lifestyle Medicine</i> , 2015, 9, 298-307.	0.8	11
97	Recognizing Sex Similarities in Cardiovascular Disease Research. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2152-2153.	1.2	3
98	Female-Specific Factors for IHD: Across the Reproductive Lifespan. <i>Current Atherosclerosis Reports</i> , 2015, 17, 481.	2.0	5
99	Gender, Cardiovascular Disease, and the Sexism of Obesity —. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1958-1960.	1.2	18
100	Towards elimination of the dark-rim artifact in first-pass myocardial perfusion MRI: Removing Gibbs ringing effects using optimized radial imaging. <i>Magnetic Resonance in Medicine</i> , 2014, 72, 124-136.	1.9	31
101	Statin therapy in women. <i>Menopause</i> , 2014, 21, 896-898.	0.8	5
102	Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women. <i>Menopause</i> , 2014, 21, 260-266.	0.8	89
103	Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. <i>American Heart Journal</i> , 2014, 167, 826-832.	1.2	33
104	A randomized controlled trial of acupuncture in stable ischemic heart disease patients. <i>International Journal of Cardiology</i> , 2014, 176, 367-374.	0.8	31
105	Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). <i>International Journal of Cardiology</i> , 2014, 172, e114-e115.	0.8	9
106	Maternal Recall of Hypertensive Disorders in Pregnancy: A Systematic Review. <i>Journal of Women's Health</i> , 2013, 22, 37-47.	1.5	85
107	Eliminating dark-rim artifacts in first-pass myocardial perfusion imaging. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, O3.	1.6	5
108	SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION (WISE). <i>Journal of the American College of Cardiology</i> , 2013, 61, E825.	1.2	2

#	ARTICLE	IF	CITATIONS
109	Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval. <i>Annals of Noninvasive Electrocardiology</i> , 2013, 18, 389-398.	0.5	21
110	Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. <i>Cardiovascular Diagnosis and Therapy</i> , 2013, 3, 153-60.	0.7	43
111	Management of Estrogen Deficiency. , 2013, , 309-317.		0
112	Cardiac risk factors and myocardial perfusion reserve in women with microvascular coronary dysfunction. <i>Cardiovascular Diagnosis and Therapy</i> , 2013, 3, 146-52.	0.7	13
113	Contraception in Patients With Heart Failure. <i>Circulation</i> , 2012, 126, 1396-1400.	1.6	13
114	Subendocardial Ischemia and Myocarditis in Systemic Lupus Erythematosus Detected by Cardiac Magnetic Resonance Imaging. <i>Journal of Rheumatology</i> , 2012, 39, 448-450.	1.0	6
115	A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. <i>Menopause</i> , 2012, 19, 54-61.	0.8	43
116	Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder. <i>Clinical Investigation</i> , 2012, 2, 423-432.	0.0	7
117	Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women: A Pilot Study. <i>Journal of Women's Health</i> , 2012, 21, 281-284.	1.5	33
118	Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 646-653.	1.1	177
119	Sex Hormones and the QT Interval: A Review. <i>Journal of Women's Health</i> , 2012, 21, 933-941.	1.5	104
120	Projection imaging of myocardial perfusion: minimizing the subendocardial dark-rim artifact. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, .	1.6	3
121	Reproducibility of myocardial perfusion reserve - variations in measurements from post processing using commercially available software. <i>Cardiovascular Diagnosis and Therapy</i> , 2012, 2, 268-77.	0.7	19
122	Therapy for stable angina in women. <i>P and T</i> , 2012, 37, 400-4.	1.0	2
123	Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease in Systemic Lupus Erythematosus. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 27-33.	2.3	138
124	Ranolazine Improves Angina in Women With Evidence of Myocardial Ischemia But No Obstructive Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 514-522.	2.3	180
125	Timing of hormone therapy, type of menopause, and coronary disease in women. <i>Menopause</i> , 2011, 18, 943-950.	0.8	29
126	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results From the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women's Ischemia Syndrome Evaluation (WISE). <i>Obstetrical and Gynecological Survey</i> , 2011, 66, 143-144.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Treatment of Angina and Microvascular Coronary Dysfunction. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 355-364.	0.4	39
128	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4985-4992.	1.8	101
129	Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question. Maturitas, 2010, 65, 297-298.	1.0	7
130	Diastolic dysfunction: Improved understanding using emerging imaging techniques. American Heart Journal, 2010, 160, 394-404.	1.2	62
131	Persistent Chest Pain and No Obstructive Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2009, 301, 1468.	3.8	67
132	Do Faculty Intensivists Have Better Outcomes When Caring for Patients Directly in a Closed ICU versus Consulting in an Open ICU?. Hospital Practice (1995), 2009, 37, 40-50.	0.5	15
133	Safety of testosterone use in women. Maturitas, 2009, 63, 63-66.	1.0	60
134	Contraceptive Hormone Use and Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 221-231.	1.2	224
135	Testosterone and the breast. Menopause International, 2008, 14, 117-122.	1.6	43
136	Hemosiderosis is associated with accelerated decompensation and decreased survival in patients with cirrhosis. Liver International, 2005, 25, 41-48.	1.9	26
137	Refractive Error, Ocular Biometry, and Lens Opalescence in an Adult Population: The Los Angeles Latino Eye Study. , 2005, 46, 4450.		173
138	The Los Angeles Latino Eye Study*1 design, methods, and baseline data. Ophthalmology, 2004, 111, 1121-1131.	2.5	144
139	IMMUNE RECOVERY VITRITIS AND UVEITIS IN AIDS. Retina, 2001, 21, 1-9.	1.0	146
140	Optic Nerve Evaluation among Optometrists. Optometry and Vision Science, 2000, 77, 446-452.	0.6	15
141	Statistical analysis of medical data. Part II: χ^2 test. Journal of Nuclear Cardiology, 2000, 7, 263-266.	1.4	4
142	Statistical analysis of medical data. Part I: Univariable analysis. Journal of Nuclear Cardiology, 2000, 7, 146-152.	1.4	5
143	Statistical analysis of medical data. Part III: Multivariable analysis. Journal of Nuclear Cardiology, 2000, 7, 484-495.	1.4	4